About MEI Pharma (NASDAQ:MEIP)
MEI Pharma, Inc. is an oncology company. The Company is focused on the clinical development of drugs and therapies for treatment of cancer. The Company's portfolio of clinical drug candidates includes Pracinostat, ME-344 and PWT143. Pracinostat is an orally available histone deacetylase (HDAC) inhibitor indicated for the treatment of advanced hematologic diseases, such as acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). ME-344 is an isoflavone-based mitochondrial inhibitor targeting a mitochondrial component of the terminal respiratory chain complex in rapidly proliferating cells. PWT143 is an oral inhibitor of phosphatidylinositide 3-kinase (PI3K) delta, a molecular target that plays a critical role in the proliferation and survival of hematologic cancer cells. Pracinostat has been tested in multiple Phase I and Phase II clinical trials in advanced hematologic malignancies and solid tumor indications.
Industry, Sector and Symbol
Industry Bio Therapeutic Drugs
Trailing P/E Ratio-4.13207547169811
Forward P/E Ratio-2.31
Sales & Book Value
Annual Sales$23.25 million
Price / Sales3.49
Cash Flow$0.08 per share
Price / Cash28.08
Book Value$1.03 per share
Price / Book2.13
Net Income$2.67 million
Return on Equity-42.23%
Return on Assets-38.25%
MEI Pharma (NASDAQ:MEIP) Frequently Asked Questions
What is MEI Pharma's stock symbol?
MEI Pharma trades on the NASDAQ under the ticker symbol "MEIP."
How were MEI Pharma's earnings last quarter?
MEI Pharma Inc (NASDAQ:MEIP) issued its quarterly earnings data on Thursday, May, 4th. The company reported ($0.02) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.03) by $0.01. The business had revenue of $4.51 million for the quarter, compared to analysts' expectations of $5 million. MEI Pharma had a negative return on equity of 42.23% and a negative net margin of 354.10%. View MEI Pharma's Earnings History.
Where is MEI Pharma's stock going? Where will MEI Pharma's stock price be in 2018?
2 brokerages have issued 1-year price objectives for MEI Pharma's shares. Their forecasts range from $6.50 to $7.00. On average, they expect MEI Pharma's stock price to reach $6.75 in the next year. View Analyst Ratings for MEI Pharma.
What are Wall Street analysts saying about MEI Pharma stock?
Here are some recent quotes from research analysts about MEI Pharma stock:
- 1. According to Zacks Investment Research, "MEI Pharma, Inc. is an oncology company focused on the clinical development of novel therapeutics targeting cancer metabolism. The Company is focused on the clinical development of its two lead isoflavone-based drug candidates, ME-143 and ME-344. MEI Pharma, Inc., formerly known as Marshall Edwards, Inc., is based in San Diego. " (2/10/2018)
- 2. Cann analysts commented, "MEI Pharma’s F2Q loss per share of $0.16 was higher than our estimated $0.09, due to operating expenses of $6.5 million, or 50.2% higher than our estimated $4.3 million. The higher than estimated expenses stemmed primarily from higher R&D expenses and costs associated with collaboration revenues. Higher R&D expenses are attributed to voruciclib expenses and increased R&D for ME-401. Our outlook for FY2019-23 revenue remains basically unchanged. Our FY2018 loss per share foreacast is being increased by 12% to account for higher anticipated R&D expense and costs associated with collaboration revenue." (2/8/2018)
Who are some of MEI Pharma's key competitors?
Some companies that are related to MEI Pharma include Summit Therapeutics (SMMT), Sierra Oncology (SRRA), Conatus Pharmaceuticals (CNAT), Verona Pharma (VRP), Ra Pharmaceuticals (RARX), Spring Bank Pharmaceuticals (SBPH), Allena Pharmaceuticals (ALNA), Dimension Therapeutics (DMTX), Fennec Pharmaceuticals (FENC), Intec Pharma (NTEC), Spero Therapeutics (SPRO), Aldeyra Therapeutics (ALDX), Forward Pharma A/S (FWP), Verastem (VSTM), Cidara Therapeutics (CDTX), Acer Therapeutics (ACER), Alpine Immune Sciences (ALPN) and RedHill Biopharma (RDHL).
Who are MEI Pharma's key executives?
MEI Pharma's management team includes the folowing people:
- Christine Anna White M.D., Independent Chairman of the Board (Age 65)
- Daniel P. Gold Ph.D., President, Chief Executive Officer, Director (Age 62)
- Brian G. Drazba, Chief Financial Officer, Secretary (Age 54)
- David M. Urso, Senior Vice President of Corporate Development, General Counsel (Age 52)
- Robert D. Mass M.D., Chief Medical Officer (Age 60)
- Charles V. Baltic III, Independent Director (Age 55)
- Kevan E. Clemens Ph.D., Independent Director (Age 72)
- Nicholas R. Glover Ph.D., Independent Director (Age 48)
- Thomas C. Reynolds M.D. Ph.D., Independent Director (Age 57)
- William Dodge Rueckert, Independent Director (Age 64)
Who owns MEI Pharma stock?
MEI Pharma's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Renaissance Technologies LLC (5.44%), Acadian Asset Management LLC (1.33%) and Deutsche Bank AG (0.62%). View Institutional Ownership Trends for MEI Pharma.
Who sold MEI Pharma stock? Who is selling MEI Pharma stock?
Who bought MEI Pharma stock? Who is buying MEI Pharma stock?
How do I buy MEI Pharma stock?
Shares of MEI Pharma can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is MEI Pharma's stock price today?
One share of MEI Pharma stock can currently be purchased for approximately $2.19.
How big of a company is MEI Pharma?
MEI Pharma has a market capitalization of $80.92 million and generates $23.25 million in revenue each year. The company earns $2.67 million in net income (profit) each year or ($0.53) on an earnings per share basis. MEI Pharma employs 25 workers across the globe.
How can I contact MEI Pharma?
MEI Pharma's mailing address is 3611 Valley Centre Dr Ste 500, SAN DIEGO, CA 92130-3324, United States. The company can be reached via phone at +1-858-7926300 or via email at [email protected]
MarketBeat Community Rating for MEI Pharma (MEIP)MarketBeat's community ratings are surveys of what our community members think about MEI Pharma and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
MEI Pharma (NASDAQ:MEIP) Earnings History and Estimates Chart
MEI Pharma (NASDAQ MEIP) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|11/8/2017||Q1 2018||($0.17)||($0.24)||$0.70 million||$0.28 million||View||N/A|
|9/5/2017||Q4 2017||($0.15)||($0.12)||$0.60 million||$0.45 million||View||Listen|
|5/4/2017||Q3 2017||($0.03)||($0.02)||$5.00 million||$4.51 million||View||N/A|
|2/8/2017||Q217||($0.29)||$0.32||$1.25 million||$17.20 million||View||N/A|
|11/8/2016||Q1 2017||($0.14)||($0.12)||$0.63 million||$1.10 million||View||N/A|
MEI Pharma (NASDAQ:MEIP) Earnings Estimates
2018 EPS Consensus Estimate: ($0.57)
(Earnings estimates data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for MEI Pharma (NASDAQ:MEIP)
No dividend announcements for this company have been tracked by MarketBeat.com
MEI Pharma (NASDAQ MEIP) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 5.25%
Institutional Ownership Percentage: 21.51%
MEI Pharma (NASDAQ MEIP) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|11/27/2017||Charles V Baltic III||Director||Buy||11,000||$2.25||$24,750.00||13,250|| |
|11/9/2015||Vivo Ventures Vii, Llc||Major Shareholder||Sell||390,572||$1.84||$718,652.48|| |
|1/21/2015||Charles V Baltic III||Director||Buy||5,000||$3.81||$19,050.00|| |
|12/9/2014||Leaf Ventures Ii L.P. New||Major Shareholder||Sell||79,085||$6.01||$475,300.85|| |
|12/8/2014||Leaf Ventures Ii L.P. New||Major Shareholder||Sell||9,004||$6.05||$54,474.20|| |
|6/30/2014||Charles V Baltic III||Director||Buy||2,000||$6.56||$13,120.00|| |
|10/29/2013||Vivo Ventures Vii, Llc||Major Shareholder||Sell||299,609||$8.21||$2,459,789.89|| |
|10/2/2013||Vivo Ventures Vii, Llc||Major Shareholder||Sell||581,646||$10.16||$5,909,523.36|| |
|8/16/2013||Charles V Baltic III||Director||Buy||2,600||$6.82||$17,732.00|| |
|6/28/2013||Vivo Ventures Vii, Llc||Major Shareholder||Sell||7,337||$7.58||$55,614.46|| |
|6/11/2013||Vivo Ventures V, Llc||Major Shareholder||Sell||13,727||$7.80||$107,070.60|| |
|5/16/2013||Vivo Ventures Vii, Llc||Major Shareholder||Sell||17,428||$9.07||$158,071.96|| |
|5/8/2013||Leaf Ventures Ii L.P. New||Major Shareholder||Sell||200,000||$8.58||$1,716,000.00|| |
|1/25/2013||Charles V Baltic III||Director||Buy||10,200||$6.04||$61,608.00|| |
|12/21/2012||Charles V Baltic III||Director||Buy||3,500||$7.18||$25,130.00|| |
MEI Pharma (NASDAQ MEIP) News Headlines
|MEI Pharma's early-stage study of ME-344 in HER2-negative breast cancer to continue as planned; shares up 1% - Seeking Alpha|
seekingalpha.com - February 14 at 7:27 AM
|MEI Pharma (MEIP) Says Interim Data Review Supports Continuation of Clinical Study Evaluating ME-344 in Patients ... - StreetInsider.com|
www.streetinsider.com - February 14 at 7:27 AM
|MEI Pharma Interim Data Review Supports Continuation of Clinical Study Evaluating ME-344 in Patients with Breast Cancer|
finance.yahoo.com - February 13 at 3:28 PM
|MEI Pharma (MEIP) Rating Increased to Hold at Zacks Investment Research|
www.americanbankingnews.com - February 10 at 7:24 AM
|MEI Pharma Reports Second Quarter Fiscal Year 2018 Results - PR Newswire (press release)|
www.prnewswire.com - February 9 at 7:16 AM
|MEI Pharma Reports Second Quarter Fiscal Year 2018 Results|
finance.yahoo.com - February 8 at 3:28 PM
|Cann Reaffirms Buy Rating for MEI Pharma (MEIP)|
www.americanbankingnews.com - February 8 at 2:38 PM
|Head-To-Head Contrast: Gemphire Therapeutics (GEMP) versus MEI Pharma (MEIP)|
www.americanbankingnews.com - January 28 at 9:14 PM
|MEI Pharma (MEIP) versus Its Competitors Head to Head Analysis|
www.americanbankingnews.com - January 14 at 11:30 AM
|ETF Preview: ETFs, Futures Strain to Recover from Weakness Sparked by Bond-Market Woes; Street Mulls Jobless Claims, PPI Data|
www.nasdaq.com - January 11 at 9:33 AM
|MEI Pharma (MEIP) Granted FDA Clearance of Investigational New Drug Application for CDK Inhibitor Voruciclib|
www.streetinsider.com - January 8 at 5:42 PM
|Critical Comparison: MEI Pharma (MEIP) & Its Rivals|
www.americanbankingnews.com - January 3 at 11:30 PM
|Head to Head Comparison: MEI Pharma (MEIP) & The Competition|
www.americanbankingnews.com - January 1 at 7:28 AM
|MEI Pharma (MEIP) vs. The Competition Critical Contrast|
www.americanbankingnews.com - December 29 at 7:24 PM
|MEI Pharma (MEIP) versus The Competition Head-To-Head Analysis|
www.americanbankingnews.com - December 29 at 5:28 AM
|ETFs with exposure to MEI Pharma, Inc. : December 25, 2017|
finance.yahoo.com - December 25 at 3:30 PM
|MEI Pharma (MEIP) Says Study of Clinical Stage Oral CDK Inhibitor Voruciclib Published in Nature Scientific Reports - StreetInsider.com|
www.streetinsider.com - December 23 at 6:05 AM
|MEI Pharma's (MEIP) Buy Rating Reaffirmed at Cann|
www.americanbankingnews.com - December 21 at 4:28 PM
|MEI Pharma (MEIP) Given a $7.00 Price Target at Oppenheimer|
www.americanbankingnews.com - December 21 at 4:28 PM
|MEI Pharma Announces Study of Clinical Stage Oral CDK Inhibitor Voruciclib Published in Nature Scientific Reports|
finance.yahoo.com - December 21 at 9:14 AM
|ETFs with exposure to MEI Pharma, Inc. : December 12, 2017|
finance.yahoo.com - December 12 at 6:01 PM
|MEI Pharma's (MEIP) Buy Rating Reiterated at Oppenheimer|
www.americanbankingnews.com - December 11 at 5:08 PM
|MEI Pharma (MEIP) Receives "Buy" Rating from Cann|
www.americanbankingnews.com - December 11 at 9:00 AM
|MEI Pharma (MEIP) Rating Lowered to Sell at ValuEngine|
www.americanbankingnews.com - December 3 at 8:14 AM
|MEI Pharma Inc (MEIP) Director Charles V. Baltic III Acquires 11,000 Shares|
www.americanbankingnews.com - November 29 at 8:46 PM
|Short Interest in MEI Pharma Inc (MEIP) Drops By 82.9%|
www.americanbankingnews.com - November 29 at 2:38 AM
|MEI Pharma to Host Annual Meeting of Stockholders|
finance.yahoo.com - November 23 at 6:26 AM
|ETFs with exposure to MEI Pharma, Inc. : November 20, 2017|
finance.yahoo.com - November 21 at 5:43 AM
|MEI Pharma (MEIP) Presents At Stifel 2017 Healthcare Conference - Slideshow|
seekingalpha.com - November 17 at 3:58 PM
|Oppenheimer Holdings Brokers Increase Earnings Estimates for MEI Pharma, Inc. (MEIP)|
www.americanbankingnews.com - November 13 at 6:34 AM
|MEI Pharma, Inc. :MEIP-US: Earnings Analysis: Q1, 2018 By the Numbers : November 9, 2017|
finance.yahoo.com - November 12 at 6:20 AM
|ETFs with exposure to MEI Pharma, Inc. : November 10, 2017|
finance.yahoo.com - November 12 at 6:20 AM
|Galectin Therapeutics (GALT) in Focus: Stock Moves 6.5% Higher|
www.zacks.com - October 12 at 12:17 AM
|Insmed (INSM) & MEI Pharma (MEIP) Head-To-Head Contrast|
www.americanbankingnews.com - October 4 at 4:32 PM
|AcelRx Pharmaceuticals (ACRX) in Focus: Stock Moves 19.6% Higher|
www.zacks.com - October 3 at 10:16 AM
|MEI Pharma to Present at Cantor Fitzgerald Global Healthcare Conference|
finance.yahoo.com - September 20 at 6:16 AM
|Featured Company News - Teva Pharmaceuticals Presents Outcome Measure Results from Phase-III Clinical Trials for the Potential of Fremanezumab to Treat Migraine Patients|
finance.yahoo.com - September 13 at 6:29 AM
|MEI Pharma (MEIP) Presents At 24th Annual NewsMakers in the Biotech Industry - Slideshow|
seekingalpha.com - September 12 at 1:07 AM
|Oppenheimer Holdings Equities Analysts Reduce Earnings Estimates for MEI Pharma, Inc. (MEIP)|
www.americanbankingnews.com - September 11 at 4:44 AM
|FY2022 Earnings Estimate for MEI Pharma, Inc. Issued By Oppenheimer Holdings (MEIP)|
www.americanbankingnews.com - September 8 at 1:18 PM
|MEI Pharma-Presage Biosciences on License Deal for Voruciclib - Nasdaq|
www.nasdaq.com - September 8 at 3:43 AM
|MEI Pharma-Presage Biosciences on License Deal for Voruciclib|
finance.yahoo.com - September 7 at 5:01 AM
|MEI Pharma, Inc. (MEIP) Issues Quarterly Earnings Results|
www.americanbankingnews.com - September 6 at 9:09 AM
|Edited Transcript of MEIP earnings conference call or presentation 5-Sep-17 1:00pm GMT|
finance.yahoo.com - September 6 at 4:08 AM
|12 Biggest Mid-Day Gainers For Tuesday | Benzinga - Benzinga|
www.benzinga.com - September 5 at 11:06 PM
|Earnings Scheduled For September 5, 2017 | Benzinga - Benzinga|
www.benzinga.com - September 5 at 5:06 PM
|MEI Pharma Announces Exclusive License Agreement with Presage Biosciences for Voruciclib, An Oral, Selective CDK ... - PR Newswire (press release)|
www.prnewswire.com - September 5 at 5:06 PM
|MEI Pharma Reports Fiscal Year 2017 Results|
finance.yahoo.com - September 5 at 5:06 PM
|MEI Pharma Announces Exclusive License Agreement with Presage Biosciences for Voruciclib, An Oral, Selective CDK Inhibitor|
finance.yahoo.com - September 5 at 5:06 PM
|MEI Pharma to Present at Two Upcoming Investor Conferences - PR Newswire (press release)|
www.prnewswire.com - September 2 at 7:35 PM
MEI Pharma (NASDAQ:MEIP) SEC Filings
This page is loading this company's SEC Filings. Please wait...
MEI Pharma (NASDAQ:MEIP) Income Statement, Balance Sheet and Cash Flow Statement
MEI Pharma (NASDAQ MEIP) Stock Chart for Friday, February, 23, 2018